Alloy Therapeutics, a biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services, announced a $40 million Series E financing round, marking a significant step in the company's evolution from antibody discovery pioneer to full-stack biotech infrastructure company. This latest round of financing values Alloy at $1 billion.

Major investors in the Series E included 8VC, JIC Venture Growth Investments, Echo Capital and multiple family offices who joined Alloy's existing investors Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, and Ulysses Diversified Holdings.